Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
Sandoz launches generic lenalidomide in 19 European countries
Sandoz announced the launch of generic oncology medicine lenalidomide, which was to become available in 19 countries across Europe.
2021
Sandoz completes acquisition of GSK’s cephalosporin antibiotics business
Sandoz, a Novartis division, completed its acquisition of GSK’s cephalosporin antibiotics business on October 11, 2021.
2020
Astellas files patent-infringement complaint against pharmaceutical companies
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the ’780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.
2020
Sandoz and Civica Rx announce injectable medicines supply agreement
Sandoz announced a five-year agreement with Civica Rx to manufacture and supply six injectable generic medicines for use at Civica's U.S. member hospitals. Initial supply was expected to begin shipping later in 2020.
2020
Novartis and Aurobindo terminate planned Sandoz business sale
Novartis announced that it and Aurobindo Pharma USA mutually agreed to terminate their agreement for the sale of Sandoz's US generic oral solids and dermatology businesses after U.S. Federal Trade Commission approval was not obtained within the anticipated timelines. Sandoz will continue operating those businesses.
2020
Sandoz completes acquisition of Aspen’s Japanese operations
Sandoz completed its acquisition of the Japanese business of Aspen Global Incorporated, acquiring all shares in Aspen Japan K.K. and associated assets held by AGI.
2019
Sandoz recalls ranitidine capsules over NDMA contamination
Sandoz Inc. voluntarily recalled all quantities and lots within expiry of its Ranitidine Hydrochloride Capsules in the US to the consumer level after confirmed contamination with NDMA above FDA-established levels in batches of the product. The company said it had received no reports of related adverse events to date.